nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0798	0.184	CbGbCtD
Ziprasidone—CYP3A7—Progesterone—uterine cancer	0.0798	0.184	CbGbCtD
Ziprasidone—CYP3A5—Progesterone—uterine cancer	0.0599	0.138	CbGbCtD
Ziprasidone—CYP1A2—Progesterone—uterine cancer	0.0446	0.102	CbGbCtD
Ziprasidone—CYP2D6—Progesterone—uterine cancer	0.0367	0.0844	CbGbCtD
Ziprasidone—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0352	0.081	CbGbCtD
Ziprasidone—CYP3A5—Etoposide—uterine cancer	0.0268	0.0616	CbGbCtD
Ziprasidone—CYP3A4—Progesterone—uterine cancer	0.0233	0.0537	CbGbCtD
Ziprasidone—CYP1A2—Etoposide—uterine cancer	0.0199	0.0459	CbGbCtD
Ziprasidone—CHRM3—ureter—uterine cancer	0.0123	0.0952	CbGeAlD
Ziprasidone—CYP2D6—Doxorubicin—uterine cancer	0.0112	0.0258	CbGbCtD
Ziprasidone—CYP3A4—Etoposide—uterine cancer	0.0104	0.024	CbGbCtD
Ziprasidone—CHRM3—muscle of abdomen—uterine cancer	0.00883	0.0685	CbGeAlD
Ziprasidone—H1F0—semen—uterine cancer	0.0088	0.0683	CbGeAlD
Ziprasidone—CYP3A4—Doxorubicin—uterine cancer	0.00712	0.0164	CbGbCtD
Ziprasidone—H1F0—oviduct—uterine cancer	0.00646	0.0501	CbGeAlD
Ziprasidone—HTR1E—myometrium—uterine cancer	0.0035	0.0271	CbGeAlD
Ziprasidone—HTR1B—artery—uterine cancer	0.00342	0.0266	CbGeAlD
Ziprasidone—HTR1D—artery—uterine cancer	0.00331	0.0257	CbGeAlD
Ziprasidone—HTR7—artery—uterine cancer	0.00264	0.0205	CbGeAlD
Ziprasidone—CHRM3—exocrine gland—uterine cancer	0.00242	0.0188	CbGeAlD
Ziprasidone—H1F0—myometrium—uterine cancer	0.00207	0.016	CbGeAlD
Ziprasidone—CHRM5—epithelium—uterine cancer	0.00188	0.0146	CbGeAlD
Ziprasidone—HTR1E—female gonad—uterine cancer	0.00185	0.0144	CbGeAlD
Ziprasidone—HTR2A—artery—uterine cancer	0.00165	0.0128	CbGeAlD
Ziprasidone—H1F0—uterine cervix—uterine cancer	0.00161	0.0125	CbGeAlD
Ziprasidone—ADRA1B—renal system—uterine cancer	0.00159	0.0124	CbGeAlD
Ziprasidone—H1F0—smooth muscle tissue—uterine cancer	0.00156	0.0121	CbGeAlD
Ziprasidone—DRD5—female reproductive system—uterine cancer	0.00156	0.0121	CbGeAlD
Ziprasidone—H1F0—decidua—uterine cancer	0.00153	0.0119	CbGeAlD
Ziprasidone—H1F0—renal system—uterine cancer	0.0015	0.0117	CbGeAlD
Ziprasidone—H1F0—endometrium—uterine cancer	0.00145	0.0113	CbGeAlD
Ziprasidone—DRD5—female gonad—uterine cancer	0.00142	0.011	CbGeAlD
Ziprasidone—H1F0—mammalian vulva—uterine cancer	0.00141	0.0109	CbGeAlD
Ziprasidone—H1F0—uterus—uterine cancer	0.00134	0.0104	CbGeAlD
Ziprasidone—H1F0—female reproductive system—uterine cancer	0.0012	0.00935	CbGeAlD
Ziprasidone—KCNH2—myometrium—uterine cancer	0.00119	0.00922	CbGeAlD
Ziprasidone—ADRA2C—myometrium—uterine cancer	0.00117	0.00909	CbGeAlD
Ziprasidone—H1F0—female gonad—uterine cancer	0.0011	0.00851	CbGeAlD
Ziprasidone—H1F0—vagina—uterine cancer	0.00109	0.00845	CbGeAlD
Ziprasidone—CHRM3—smooth muscle tissue—uterine cancer	0.00101	0.00786	CbGeAlD
Ziprasidone—HTR7—epithelium—uterine cancer	0.001	0.00777	CbGeAlD
Ziprasidone—CHRM3—renal system—uterine cancer	0.000975	0.00757	CbGeAlD
Ziprasidone—HTR1A—renal system—uterine cancer	0.000971	0.00754	CbGeAlD
Ziprasidone—ADRA1A—epithelium—uterine cancer	0.000965	0.00749	CbGeAlD
Ziprasidone—HTR7—smooth muscle tissue—uterine cancer	0.000964	0.00748	CbGeAlD
Ziprasidone—HTR1B—female reproductive system—uterine cancer	0.000964	0.00748	CbGeAlD
Ziprasidone—HRH1—myometrium—uterine cancer	0.000952	0.00739	CbGeAlD
Ziprasidone—ADRA2A—myometrium—uterine cancer	0.000935	0.00726	CbGeAlD
Ziprasidone—HTR1D—female reproductive system—uterine cancer	0.000933	0.00724	CbGeAlD
Ziprasidone—HTR7—renal system—uterine cancer	0.000928	0.0072	CbGeAlD
Ziprasidone—KCNH2—uterine cervix—uterine cancer	0.000924	0.00717	CbGeAlD
Ziprasidone—HTR2C—female reproductive system—uterine cancer	0.000924	0.00717	CbGeAlD
Ziprasidone—ADRA2C—uterine cervix—uterine cancer	0.000912	0.00708	CbGeAlD
Ziprasidone—ADRA1A—renal system—uterine cancer	0.000895	0.00695	CbGeAlD
Ziprasidone—SLC6A4—female reproductive system—uterine cancer	0.000876	0.0068	CbGeAlD
Ziprasidone—CHRM1—female reproductive system—uterine cancer	0.000873	0.00677	CbGeAlD
Ziprasidone—ADRA2C—decidua—uterine cancer	0.000869	0.00674	CbGeAlD
Ziprasidone—KCNH2—renal system—uterine cancer	0.000865	0.00671	CbGeAlD
Ziprasidone—ADRA2C—renal system—uterine cancer	0.000853	0.00662	CbGeAlD
Ziprasidone—KCNH2—endometrium—uterine cancer	0.000836	0.00649	CbGeAlD
Ziprasidone—ADRA2C—endometrium—uterine cancer	0.000825	0.0064	CbGeAlD
Ziprasidone—ADRA2C—mammalian vulva—uterine cancer	0.000798	0.00619	CbGeAlD
Ziprasidone—CHRM3—female reproductive system—uterine cancer	0.000781	0.00606	CbGeAlD
Ziprasidone—KCNH2—uterus—uterine cancer	0.00077	0.00598	CbGeAlD
Ziprasidone—CYP3A5—uterine cervix—uterine cancer	0.000763	0.00592	CbGeAlD
Ziprasidone—ADRA2C—uterus—uterine cancer	0.00076	0.0059	CbGeAlD
Ziprasidone—HRH1—epithelium—uterine cancer	0.000747	0.0058	CbGeAlD
Ziprasidone—HTR7—female reproductive system—uterine cancer	0.000743	0.00577	CbGeAlD
Ziprasidone—HRH1—uterine cervix—uterine cancer	0.000741	0.00575	CbGeAlD
Ziprasidone—CYP1A2—renal system—uterine cancer	0.00074	0.00574	CbGeAlD
Ziprasidone—ADRA2A—uterine cervix—uterine cancer	0.000728	0.00565	CbGeAlD
Ziprasidone—HRH1—smooth muscle tissue—uterine cancer	0.00072	0.00559	CbGeAlD
Ziprasidone—CYP3A5—renal system—uterine cancer	0.000714	0.00554	CbGeAlD
Ziprasidone—CHRM3—female gonad—uterine cancer	0.000711	0.00551	CbGeAlD
Ziprasidone—HRH1—decidua—uterine cancer	0.000706	0.00548	CbGeAlD
Ziprasidone—H1F0—lymph node—uterine cancer	0.000705	0.00547	CbGeAlD
Ziprasidone—ADRA2A—decidua—uterine cancer	0.000693	0.00538	CbGeAlD
Ziprasidone—KCNH2—female reproductive system—uterine cancer	0.000692	0.00537	CbGeAlD
Ziprasidone—HRH1—endometrium—uterine cancer	0.00067	0.0052	CbGeAlD
Ziprasidone—ADRA2A—endometrium—uterine cancer	0.000658	0.00511	CbGeAlD
Ziprasidone—HRH1—mammalian vulva—uterine cancer	0.000648	0.00503	CbGeAlD
Ziprasidone—ADRA2A—mammalian vulva—uterine cancer	0.000637	0.00494	CbGeAlD
Ziprasidone—KCNH2—female gonad—uterine cancer	0.00063	0.00489	CbGeAlD
Ziprasidone—KCNH2—vagina—uterine cancer	0.000626	0.00486	CbGeAlD
Ziprasidone—HTR2A—epithelium—uterine cancer	0.000624	0.00484	CbGeAlD
Ziprasidone—ADRA2C—female gonad—uterine cancer	0.000622	0.00482	CbGeAlD
Ziprasidone—ADRA2C—vagina—uterine cancer	0.000618	0.00479	CbGeAlD
Ziprasidone—ADRA2A—uterus—uterine cancer	0.000606	0.00471	CbGeAlD
Ziprasidone—HTR2A—smooth muscle tissue—uterine cancer	0.000601	0.00467	CbGeAlD
Ziprasidone—HTR2A—renal system—uterine cancer	0.000579	0.00449	CbGeAlD
Ziprasidone—HRH1—female reproductive system—uterine cancer	0.000555	0.00431	CbGeAlD
Ziprasidone—ADRA2A—female reproductive system—uterine cancer	0.000545	0.00423	CbGeAlD
Ziprasidone—CYP3A4—renal system—uterine cancer	0.000536	0.00416	CbGeAlD
Ziprasidone—CYP2D6—renal system—uterine cancer	0.000527	0.00409	CbGeAlD
Ziprasidone—CYP3A5—female gonad—uterine cancer	0.00052	0.00404	CbGeAlD
Ziprasidone—CYP3A5—vagina—uterine cancer	0.000517	0.00401	CbGeAlD
Ziprasidone—HRH1—female gonad—uterine cancer	0.000505	0.00392	CbGeAlD
Ziprasidone—HRH1—vagina—uterine cancer	0.000502	0.0039	CbGeAlD
Ziprasidone—ADRA2A—female gonad—uterine cancer	0.000496	0.00385	CbGeAlD
Ziprasidone—ADRA2A—vagina—uterine cancer	0.000493	0.00383	CbGeAlD
Ziprasidone—HTR2A—female reproductive system—uterine cancer	0.000464	0.0036	CbGeAlD
Ziprasidone—CYP3A4—female reproductive system—uterine cancer	0.000429	0.00333	CbGeAlD
Ziprasidone—CYP2D6—female reproductive system—uterine cancer	0.000422	0.00328	CbGeAlD
Ziprasidone—HTR2A—vagina—uterine cancer	0.000419	0.00325	CbGeAlD
Ziprasidone—KCNH2—lymph node—uterine cancer	0.000405	0.00314	CbGeAlD
Ziprasidone—ADRA2C—lymph node—uterine cancer	0.0004	0.0031	CbGeAlD
Ziprasidone—CYP2D6—female gonad—uterine cancer	0.000384	0.00298	CbGeAlD
Ziprasidone—HRH1—lymph node—uterine cancer	0.000325	0.00252	CbGeAlD
Ziprasidone—ADRA2A—lymph node—uterine cancer	0.000319	0.00247	CbGeAlD
Ziprasidone—Pain in extremity—Doxorubicin—uterine cancer	0.000207	0.000536	CcSEcCtD
Ziprasidone—Diplopia—Doxorubicin—uterine cancer	0.000207	0.000536	CcSEcCtD
Ziprasidone—Liver function test abnormal—Epirubicin—uterine cancer	0.000207	0.000535	CcSEcCtD
Ziprasidone—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000207	0.000535	CcSEcCtD
Ziprasidone—Chest pain—Etoposide—uterine cancer	0.000205	0.00053	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Epirubicin—uterine cancer	0.000204	0.000529	CcSEcCtD
Ziprasidone—Hypokalaemia—Epirubicin—uterine cancer	0.000204	0.000527	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000203	0.000526	CcSEcCtD
Ziprasidone—Breast disorder—Epirubicin—uterine cancer	0.000202	0.000524	CcSEcCtD
Ziprasidone—Nasopharyngitis—Epirubicin—uterine cancer	0.0002	0.000518	CcSEcCtD
Ziprasidone—Face oedema—Doxorubicin—uterine cancer	0.0002	0.000518	CcSEcCtD
Ziprasidone—Hypersensitivity—Dactinomycin—uterine cancer	0.0002	0.000517	CcSEcCtD
Ziprasidone—Gastritis—Epirubicin—uterine cancer	0.000198	0.000513	CcSEcCtD
Ziprasidone—Confusional state—Etoposide—uterine cancer	0.000198	0.000512	CcSEcCtD
Ziprasidone—Infection—Etoposide—uterine cancer	0.000195	0.000505	CcSEcCtD
Ziprasidone—Ataxia—Doxorubicin—uterine cancer	0.000195	0.000504	CcSEcCtD
Ziprasidone—Asthenia—Dactinomycin—uterine cancer	0.000195	0.000504	CcSEcCtD
Ziprasidone—Blood creatinine increased—Doxorubicin—uterine cancer	0.000194	0.000502	CcSEcCtD
Ziprasidone—Dysphagia—Epirubicin—uterine cancer	0.000193	0.000501	CcSEcCtD
Ziprasidone—Influenza—Epirubicin—uterine cancer	0.000193	0.000501	CcSEcCtD
Ziprasidone—Dehydration—Doxorubicin—uterine cancer	0.000193	0.000499	CcSEcCtD
Ziprasidone—Thrombocytopenia—Etoposide—uterine cancer	0.000192	0.000498	CcSEcCtD
Ziprasidone—Tachycardia—Etoposide—uterine cancer	0.000192	0.000496	CcSEcCtD
Ziprasidone—Eosinophilia—Epirubicin—uterine cancer	0.000192	0.000496	CcSEcCtD
Ziprasidone—Liver function test abnormal—Doxorubicin—uterine cancer	0.000191	0.000495	CcSEcCtD
Ziprasidone—Skin disorder—Etoposide—uterine cancer	0.000191	0.000494	CcSEcCtD
Ziprasidone—Hyperhidrosis—Etoposide—uterine cancer	0.00019	0.000491	CcSEcCtD
Ziprasidone—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000189	0.00049	CcSEcCtD
Ziprasidone—Hypokalaemia—Doxorubicin—uterine cancer	0.000189	0.000488	CcSEcCtD
Ziprasidone—Angina pectoris—Epirubicin—uterine cancer	0.000188	0.000488	CcSEcCtD
Ziprasidone—Breast disorder—Doxorubicin—uterine cancer	0.000187	0.000485	CcSEcCtD
Ziprasidone—Anorexia—Etoposide—uterine cancer	0.000187	0.000484	CcSEcCtD
Ziprasidone—Diarrhoea—Dactinomycin—uterine cancer	0.000186	0.00048	CcSEcCtD
Ziprasidone—Nasopharyngitis—Doxorubicin—uterine cancer	0.000185	0.00048	CcSEcCtD
Ziprasidone—Hypotension—Etoposide—uterine cancer	0.000183	0.000475	CcSEcCtD
Ziprasidone—Gastritis—Doxorubicin—uterine cancer	0.000183	0.000475	CcSEcCtD
Ziprasidone—Dysuria—Epirubicin—uterine cancer	0.000181	0.000468	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Epirubicin—uterine cancer	0.00018	0.000466	CcSEcCtD
Ziprasidone—Influenza—Doxorubicin—uterine cancer	0.000179	0.000463	CcSEcCtD
Ziprasidone—Dysphagia—Doxorubicin—uterine cancer	0.000179	0.000463	CcSEcCtD
Ziprasidone—Eosinophilia—Doxorubicin—uterine cancer	0.000177	0.000459	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Epirubicin—uterine cancer	0.000177	0.000457	CcSEcCtD
Ziprasidone—Paraesthesia—Etoposide—uterine cancer	0.000176	0.000456	CcSEcCtD
Ziprasidone—Weight increased—Epirubicin—uterine cancer	0.000176	0.000456	CcSEcCtD
Ziprasidone—Weight decreased—Epirubicin—uterine cancer	0.000175	0.000453	CcSEcCtD
Ziprasidone—Dyspnoea—Etoposide—uterine cancer	0.000175	0.000453	CcSEcCtD
Ziprasidone—Hyperglycaemia—Epirubicin—uterine cancer	0.000175	0.000452	CcSEcCtD
Ziprasidone—Somnolence—Etoposide—uterine cancer	0.000175	0.000452	CcSEcCtD
Ziprasidone—Angina pectoris—Doxorubicin—uterine cancer	0.000174	0.000451	CcSEcCtD
Ziprasidone—Pneumonia—Epirubicin—uterine cancer	0.000174	0.000449	CcSEcCtD
Ziprasidone—Infestation NOS—Epirubicin—uterine cancer	0.000173	0.000447	CcSEcCtD
Ziprasidone—Infestation—Epirubicin—uterine cancer	0.000173	0.000447	CcSEcCtD
Ziprasidone—Vomiting—Dactinomycin—uterine cancer	0.000172	0.000446	CcSEcCtD
Ziprasidone—Rash—Dactinomycin—uterine cancer	0.000171	0.000443	CcSEcCtD
Ziprasidone—Decreased appetite—Etoposide—uterine cancer	0.000171	0.000442	CcSEcCtD
Ziprasidone—Renal failure—Epirubicin—uterine cancer	0.00017	0.000439	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Etoposide—uterine cancer	0.000169	0.000439	CcSEcCtD
Ziprasidone—Fatigue—Etoposide—uterine cancer	0.000169	0.000438	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Epirubicin—uterine cancer	0.000169	0.000438	CcSEcCtD
Ziprasidone—Jaundice—Epirubicin—uterine cancer	0.000168	0.000435	CcSEcCtD
Ziprasidone—Constipation—Etoposide—uterine cancer	0.000168	0.000435	CcSEcCtD
Ziprasidone—Conjunctivitis—Epirubicin—uterine cancer	0.000168	0.000434	CcSEcCtD
Ziprasidone—Dysuria—Doxorubicin—uterine cancer	0.000167	0.000433	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000166	0.000431	CcSEcCtD
Ziprasidone—Sweating—Epirubicin—uterine cancer	0.000165	0.000428	CcSEcCtD
Ziprasidone—Haematuria—Epirubicin—uterine cancer	0.000164	0.000426	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000163	0.000423	CcSEcCtD
Ziprasidone—Weight increased—Doxorubicin—uterine cancer	0.000163	0.000422	CcSEcCtD
Ziprasidone—Epistaxis—Epirubicin—uterine cancer	0.000163	0.000421	CcSEcCtD
Ziprasidone—Weight decreased—Doxorubicin—uterine cancer	0.000162	0.000419	CcSEcCtD
Ziprasidone—Feeling abnormal—Etoposide—uterine cancer	0.000162	0.000419	CcSEcCtD
Ziprasidone—Hyperglycaemia—Doxorubicin—uterine cancer	0.000162	0.000418	CcSEcCtD
Ziprasidone—Nausea—Dactinomycin—uterine cancer	0.000161	0.000417	CcSEcCtD
Ziprasidone—Pneumonia—Doxorubicin—uterine cancer	0.000161	0.000416	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Etoposide—uterine cancer	0.000161	0.000416	CcSEcCtD
Ziprasidone—Infestation NOS—Doxorubicin—uterine cancer	0.00016	0.000413	CcSEcCtD
Ziprasidone—Infestation—Doxorubicin—uterine cancer	0.00016	0.000413	CcSEcCtD
Ziprasidone—Bradycardia—Epirubicin—uterine cancer	0.000158	0.000408	CcSEcCtD
Ziprasidone—Renal failure—Doxorubicin—uterine cancer	0.000157	0.000406	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000156	0.000405	CcSEcCtD
Ziprasidone—Urticaria—Etoposide—uterine cancer	0.000156	0.000404	CcSEcCtD
Ziprasidone—Haemoglobin—Epirubicin—uterine cancer	0.000156	0.000403	CcSEcCtD
Ziprasidone—Jaundice—Doxorubicin—uterine cancer	0.000156	0.000403	CcSEcCtD
Ziprasidone—Rhinitis—Epirubicin—uterine cancer	0.000155	0.000402	CcSEcCtD
Ziprasidone—Abdominal pain—Etoposide—uterine cancer	0.000155	0.000402	CcSEcCtD
Ziprasidone—Body temperature increased—Etoposide—uterine cancer	0.000155	0.000402	CcSEcCtD
Ziprasidone—Conjunctivitis—Doxorubicin—uterine cancer	0.000155	0.000402	CcSEcCtD
Ziprasidone—Haemorrhage—Epirubicin—uterine cancer	0.000155	0.000401	CcSEcCtD
Ziprasidone—Hepatitis—Epirubicin—uterine cancer	0.000155	0.000401	CcSEcCtD
Ziprasidone—Hypoaesthesia—Epirubicin—uterine cancer	0.000154	0.000399	CcSEcCtD
Ziprasidone—Pharyngitis—Epirubicin—uterine cancer	0.000154	0.000398	CcSEcCtD
Ziprasidone—Sweating—Doxorubicin—uterine cancer	0.000153	0.000396	CcSEcCtD
Ziprasidone—Urinary tract disorder—Epirubicin—uterine cancer	0.000153	0.000396	CcSEcCtD
Ziprasidone—Oedema peripheral—Epirubicin—uterine cancer	0.000153	0.000395	CcSEcCtD
Ziprasidone—Haematuria—Doxorubicin—uterine cancer	0.000152	0.000394	CcSEcCtD
Ziprasidone—Connective tissue disorder—Epirubicin—uterine cancer	0.000152	0.000394	CcSEcCtD
Ziprasidone—Urethral disorder—Epirubicin—uterine cancer	0.000152	0.000393	CcSEcCtD
Ziprasidone—Epistaxis—Doxorubicin—uterine cancer	0.000151	0.00039	CcSEcCtD
Ziprasidone—Visual impairment—Epirubicin—uterine cancer	0.000149	0.000386	CcSEcCtD
Ziprasidone—Bradycardia—Doxorubicin—uterine cancer	0.000146	0.000378	CcSEcCtD
Ziprasidone—Eye disorder—Epirubicin—uterine cancer	0.000145	0.000375	CcSEcCtD
Ziprasidone—Hypersensitivity—Etoposide—uterine cancer	0.000145	0.000374	CcSEcCtD
Ziprasidone—Tinnitus—Epirubicin—uterine cancer	0.000144	0.000374	CcSEcCtD
Ziprasidone—Haemoglobin—Doxorubicin—uterine cancer	0.000144	0.000373	CcSEcCtD
Ziprasidone—Cardiac disorder—Epirubicin—uterine cancer	0.000144	0.000372	CcSEcCtD
Ziprasidone—Rhinitis—Doxorubicin—uterine cancer	0.000144	0.000372	CcSEcCtD
Ziprasidone—Haemorrhage—Doxorubicin—uterine cancer	0.000143	0.000371	CcSEcCtD
Ziprasidone—Hepatitis—Doxorubicin—uterine cancer	0.000143	0.000371	CcSEcCtD
Ziprasidone—Hypoaesthesia—Doxorubicin—uterine cancer	0.000143	0.000369	CcSEcCtD
Ziprasidone—Pharyngitis—Doxorubicin—uterine cancer	0.000142	0.000368	CcSEcCtD
Ziprasidone—Urinary tract disorder—Doxorubicin—uterine cancer	0.000142	0.000366	CcSEcCtD
Ziprasidone—Oedema peripheral—Doxorubicin—uterine cancer	0.000141	0.000365	CcSEcCtD
Ziprasidone—Asthenia—Etoposide—uterine cancer	0.000141	0.000365	CcSEcCtD
Ziprasidone—Connective tissue disorder—Doxorubicin—uterine cancer	0.000141	0.000365	CcSEcCtD
Ziprasidone—Angiopathy—Epirubicin—uterine cancer	0.000141	0.000364	CcSEcCtD
Ziprasidone—Urethral disorder—Doxorubicin—uterine cancer	0.00014	0.000364	CcSEcCtD
Ziprasidone—Immune system disorder—Epirubicin—uterine cancer	0.00014	0.000362	CcSEcCtD
Ziprasidone—Mediastinal disorder—Epirubicin—uterine cancer	0.00014	0.000361	CcSEcCtD
Ziprasidone—Chills—Epirubicin—uterine cancer	0.000139	0.00036	CcSEcCtD
Ziprasidone—Arrhythmia—Epirubicin—uterine cancer	0.000138	0.000358	CcSEcCtD
Ziprasidone—Visual impairment—Doxorubicin—uterine cancer	0.000138	0.000357	CcSEcCtD
Ziprasidone—Alopecia—Epirubicin—uterine cancer	0.000137	0.000354	CcSEcCtD
Ziprasidone—Mental disorder—Epirubicin—uterine cancer	0.000136	0.000351	CcSEcCtD
Ziprasidone—Malnutrition—Epirubicin—uterine cancer	0.000135	0.000349	CcSEcCtD
Ziprasidone—Erythema—Epirubicin—uterine cancer	0.000135	0.000349	CcSEcCtD
Ziprasidone—Diarrhoea—Etoposide—uterine cancer	0.000134	0.000348	CcSEcCtD
Ziprasidone—Eye disorder—Doxorubicin—uterine cancer	0.000134	0.000347	CcSEcCtD
Ziprasidone—Tinnitus—Doxorubicin—uterine cancer	0.000134	0.000346	CcSEcCtD
Ziprasidone—Cardiac disorder—Doxorubicin—uterine cancer	0.000133	0.000344	CcSEcCtD
Ziprasidone—Flatulence—Epirubicin—uterine cancer	0.000133	0.000344	CcSEcCtD
Ziprasidone—Back pain—Epirubicin—uterine cancer	0.00013	0.000338	CcSEcCtD
Ziprasidone—Angiopathy—Doxorubicin—uterine cancer	0.00013	0.000337	CcSEcCtD
Ziprasidone—Dizziness—Etoposide—uterine cancer	0.00013	0.000336	CcSEcCtD
Ziprasidone—Muscle spasms—Epirubicin—uterine cancer	0.00013	0.000336	CcSEcCtD
Ziprasidone—Immune system disorder—Doxorubicin—uterine cancer	0.000129	0.000335	CcSEcCtD
Ziprasidone—Mediastinal disorder—Doxorubicin—uterine cancer	0.000129	0.000334	CcSEcCtD
Ziprasidone—Chills—Doxorubicin—uterine cancer	0.000129	0.000333	CcSEcCtD
Ziprasidone—Arrhythmia—Doxorubicin—uterine cancer	0.000128	0.000331	CcSEcCtD
Ziprasidone—Vision blurred—Epirubicin—uterine cancer	0.000127	0.000329	CcSEcCtD
Ziprasidone—Alopecia—Doxorubicin—uterine cancer	0.000127	0.000328	CcSEcCtD
Ziprasidone—Mental disorder—Doxorubicin—uterine cancer	0.000126	0.000325	CcSEcCtD
Ziprasidone—Vomiting—Etoposide—uterine cancer	0.000125	0.000323	CcSEcCtD
Ziprasidone—Erythema—Doxorubicin—uterine cancer	0.000125	0.000323	CcSEcCtD
Ziprasidone—Malnutrition—Doxorubicin—uterine cancer	0.000125	0.000323	CcSEcCtD
Ziprasidone—Anaemia—Epirubicin—uterine cancer	0.000125	0.000323	CcSEcCtD
Ziprasidone—Agitation—Epirubicin—uterine cancer	0.000124	0.000321	CcSEcCtD
Ziprasidone—Rash—Etoposide—uterine cancer	0.000124	0.00032	CcSEcCtD
Ziprasidone—Dermatitis—Etoposide—uterine cancer	0.000124	0.00032	CcSEcCtD
Ziprasidone—Headache—Etoposide—uterine cancer	0.000123	0.000318	CcSEcCtD
Ziprasidone—Flatulence—Doxorubicin—uterine cancer	0.000123	0.000318	CcSEcCtD
Ziprasidone—Vertigo—Epirubicin—uterine cancer	0.000121	0.000314	CcSEcCtD
Ziprasidone—Syncope—Epirubicin—uterine cancer	0.000121	0.000313	CcSEcCtD
Ziprasidone—Leukopenia—Epirubicin—uterine cancer	0.000121	0.000312	CcSEcCtD
Ziprasidone—Back pain—Doxorubicin—uterine cancer	0.000121	0.000312	CcSEcCtD
Ziprasidone—Muscle spasms—Doxorubicin—uterine cancer	0.00012	0.00031	CcSEcCtD
Ziprasidone—Palpitations—Epirubicin—uterine cancer	0.000119	0.000308	CcSEcCtD
Ziprasidone—Loss of consciousness—Epirubicin—uterine cancer	0.000118	0.000307	CcSEcCtD
Ziprasidone—Cough—Epirubicin—uterine cancer	0.000118	0.000305	CcSEcCtD
Ziprasidone—Vision blurred—Doxorubicin—uterine cancer	0.000118	0.000304	CcSEcCtD
Ziprasidone—Nausea—Etoposide—uterine cancer	0.000117	0.000302	CcSEcCtD
Ziprasidone—Hypertension—Epirubicin—uterine cancer	0.000116	0.000301	CcSEcCtD
Ziprasidone—Anaemia—Doxorubicin—uterine cancer	0.000115	0.000298	CcSEcCtD
Ziprasidone—Chest pain—Epirubicin—uterine cancer	0.000115	0.000297	CcSEcCtD
Ziprasidone—Myalgia—Epirubicin—uterine cancer	0.000115	0.000297	CcSEcCtD
Ziprasidone—Arthralgia—Epirubicin—uterine cancer	0.000115	0.000297	CcSEcCtD
Ziprasidone—Agitation—Doxorubicin—uterine cancer	0.000115	0.000297	CcSEcCtD
Ziprasidone—Anxiety—Epirubicin—uterine cancer	0.000114	0.000296	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000114	0.000295	CcSEcCtD
Ziprasidone—Dry mouth—Epirubicin—uterine cancer	0.000112	0.000291	CcSEcCtD
Ziprasidone—Vertigo—Doxorubicin—uterine cancer	0.000112	0.00029	CcSEcCtD
Ziprasidone—Syncope—Doxorubicin—uterine cancer	0.000112	0.00029	CcSEcCtD
Ziprasidone—Leukopenia—Doxorubicin—uterine cancer	0.000112	0.000289	CcSEcCtD
Ziprasidone—Confusional state—Epirubicin—uterine cancer	0.000111	0.000287	CcSEcCtD
Ziprasidone—Palpitations—Doxorubicin—uterine cancer	0.00011	0.000285	CcSEcCtD
Ziprasidone—Loss of consciousness—Doxorubicin—uterine cancer	0.00011	0.000284	CcSEcCtD
Ziprasidone—Infection—Epirubicin—uterine cancer	0.000109	0.000283	CcSEcCtD
Ziprasidone—Cough—Doxorubicin—uterine cancer	0.000109	0.000282	CcSEcCtD
Ziprasidone—Shock—Epirubicin—uterine cancer	0.000108	0.00028	CcSEcCtD
Ziprasidone—Nervous system disorder—Epirubicin—uterine cancer	0.000108	0.000279	CcSEcCtD
Ziprasidone—Thrombocytopenia—Epirubicin—uterine cancer	0.000108	0.000279	CcSEcCtD
Ziprasidone—Hypertension—Doxorubicin—uterine cancer	0.000108	0.000279	CcSEcCtD
Ziprasidone—Tachycardia—Epirubicin—uterine cancer	0.000107	0.000278	CcSEcCtD
Ziprasidone—Skin disorder—Epirubicin—uterine cancer	0.000107	0.000277	CcSEcCtD
Ziprasidone—Hyperhidrosis—Epirubicin—uterine cancer	0.000106	0.000275	CcSEcCtD
Ziprasidone—Chest pain—Doxorubicin—uterine cancer	0.000106	0.000275	CcSEcCtD
Ziprasidone—Arthralgia—Doxorubicin—uterine cancer	0.000106	0.000275	CcSEcCtD
Ziprasidone—Myalgia—Doxorubicin—uterine cancer	0.000106	0.000275	CcSEcCtD
Ziprasidone—Anxiety—Doxorubicin—uterine cancer	0.000106	0.000274	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000105	0.000273	CcSEcCtD
Ziprasidone—Anorexia—Epirubicin—uterine cancer	0.000105	0.000272	CcSEcCtD
Ziprasidone—Dry mouth—Doxorubicin—uterine cancer	0.000104	0.000269	CcSEcCtD
Ziprasidone—Hypotension—Epirubicin—uterine cancer	0.000103	0.000266	CcSEcCtD
Ziprasidone—Confusional state—Doxorubicin—uterine cancer	0.000103	0.000266	CcSEcCtD
Ziprasidone—Infection—Doxorubicin—uterine cancer	0.000101	0.000262	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.0001	0.00026	CcSEcCtD
Ziprasidone—Shock—Doxorubicin—uterine cancer	0.0001	0.000259	CcSEcCtD
Ziprasidone—Nervous system disorder—Doxorubicin—uterine cancer	9.98e-05	0.000258	CcSEcCtD
Ziprasidone—Thrombocytopenia—Doxorubicin—uterine cancer	9.97e-05	0.000258	CcSEcCtD
Ziprasidone—Insomnia—Epirubicin—uterine cancer	9.95e-05	0.000258	CcSEcCtD
Ziprasidone—Tachycardia—Doxorubicin—uterine cancer	9.94e-05	0.000257	CcSEcCtD
Ziprasidone—Skin disorder—Doxorubicin—uterine cancer	9.89e-05	0.000256	CcSEcCtD
Ziprasidone—Paraesthesia—Epirubicin—uterine cancer	9.88e-05	0.000256	CcSEcCtD
Ziprasidone—Hyperhidrosis—Doxorubicin—uterine cancer	9.84e-05	0.000255	CcSEcCtD
Ziprasidone—Dyspnoea—Epirubicin—uterine cancer	9.81e-05	0.000254	CcSEcCtD
Ziprasidone—Somnolence—Epirubicin—uterine cancer	9.78e-05	0.000253	CcSEcCtD
Ziprasidone—Anorexia—Doxorubicin—uterine cancer	9.7e-05	0.000251	CcSEcCtD
Ziprasidone—Dyspepsia—Epirubicin—uterine cancer	9.69e-05	0.000251	CcSEcCtD
Ziprasidone—Decreased appetite—Epirubicin—uterine cancer	9.57e-05	0.000248	CcSEcCtD
Ziprasidone—Hypotension—Doxorubicin—uterine cancer	9.51e-05	0.000246	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Epirubicin—uterine cancer	9.5e-05	0.000246	CcSEcCtD
Ziprasidone—Fatigue—Epirubicin—uterine cancer	9.49e-05	0.000246	CcSEcCtD
Ziprasidone—Constipation—Epirubicin—uterine cancer	9.41e-05	0.000244	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Doxorubicin—uterine cancer	9.28e-05	0.00024	CcSEcCtD
Ziprasidone—Insomnia—Doxorubicin—uterine cancer	9.21e-05	0.000238	CcSEcCtD
Ziprasidone—Paraesthesia—Doxorubicin—uterine cancer	9.14e-05	0.000237	CcSEcCtD
Ziprasidone—Dyspnoea—Doxorubicin—uterine cancer	9.08e-05	0.000235	CcSEcCtD
Ziprasidone—Feeling abnormal—Epirubicin—uterine cancer	9.07e-05	0.000235	CcSEcCtD
Ziprasidone—Somnolence—Doxorubicin—uterine cancer	9.05e-05	0.000234	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Epirubicin—uterine cancer	9e-05	0.000233	CcSEcCtD
Ziprasidone—Dyspepsia—Doxorubicin—uterine cancer	8.96e-05	0.000232	CcSEcCtD
Ziprasidone—Decreased appetite—Doxorubicin—uterine cancer	8.85e-05	0.000229	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Doxorubicin—uterine cancer	8.79e-05	0.000228	CcSEcCtD
Ziprasidone—Fatigue—Doxorubicin—uterine cancer	8.78e-05	0.000227	CcSEcCtD
Ziprasidone—Urticaria—Epirubicin—uterine cancer	8.74e-05	0.000226	CcSEcCtD
Ziprasidone—Constipation—Doxorubicin—uterine cancer	8.71e-05	0.000225	CcSEcCtD
Ziprasidone—Abdominal pain—Epirubicin—uterine cancer	8.7e-05	0.000225	CcSEcCtD
Ziprasidone—Body temperature increased—Epirubicin—uterine cancer	8.7e-05	0.000225	CcSEcCtD
Ziprasidone—Feeling abnormal—Doxorubicin—uterine cancer	8.39e-05	0.000217	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Doxorubicin—uterine cancer	8.33e-05	0.000216	CcSEcCtD
Ziprasidone—Hypersensitivity—Epirubicin—uterine cancer	8.11e-05	0.00021	CcSEcCtD
Ziprasidone—Urticaria—Doxorubicin—uterine cancer	8.09e-05	0.000209	CcSEcCtD
Ziprasidone—Abdominal pain—Doxorubicin—uterine cancer	8.05e-05	0.000208	CcSEcCtD
Ziprasidone—Body temperature increased—Doxorubicin—uterine cancer	8.05e-05	0.000208	CcSEcCtD
Ziprasidone—Asthenia—Epirubicin—uterine cancer	7.89e-05	0.000204	CcSEcCtD
Ziprasidone—Diarrhoea—Epirubicin—uterine cancer	7.53e-05	0.000195	CcSEcCtD
Ziprasidone—Hypersensitivity—Doxorubicin—uterine cancer	7.5e-05	0.000194	CcSEcCtD
Ziprasidone—Asthenia—Doxorubicin—uterine cancer	7.3e-05	0.000189	CcSEcCtD
Ziprasidone—Dizziness—Epirubicin—uterine cancer	7.28e-05	0.000188	CcSEcCtD
Ziprasidone—Vomiting—Epirubicin—uterine cancer	7e-05	0.000181	CcSEcCtD
Ziprasidone—Diarrhoea—Doxorubicin—uterine cancer	6.97e-05	0.00018	CcSEcCtD
Ziprasidone—Rash—Epirubicin—uterine cancer	6.94e-05	0.00018	CcSEcCtD
Ziprasidone—Dermatitis—Epirubicin—uterine cancer	6.93e-05	0.000179	CcSEcCtD
Ziprasidone—Headache—Epirubicin—uterine cancer	6.89e-05	0.000178	CcSEcCtD
Ziprasidone—Dizziness—Doxorubicin—uterine cancer	6.73e-05	0.000174	CcSEcCtD
Ziprasidone—Nausea—Epirubicin—uterine cancer	6.54e-05	0.000169	CcSEcCtD
Ziprasidone—Vomiting—Doxorubicin—uterine cancer	6.47e-05	0.000168	CcSEcCtD
Ziprasidone—Rash—Doxorubicin—uterine cancer	6.42e-05	0.000166	CcSEcCtD
Ziprasidone—Dermatitis—Doxorubicin—uterine cancer	6.41e-05	0.000166	CcSEcCtD
Ziprasidone—Headache—Doxorubicin—uterine cancer	6.38e-05	0.000165	CcSEcCtD
Ziprasidone—Nausea—Doxorubicin—uterine cancer	6.05e-05	0.000157	CcSEcCtD
Ziprasidone—HTR1B—Signaling Pathways—KRAS—uterine cancer	5.27e-06	0.000105	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—ERBB2—uterine cancer	5.27e-06	0.000105	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—ERBB2—uterine cancer	5.26e-06	0.000105	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PTEN—uterine cancer	5.23e-06	0.000105	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PTEN—uterine cancer	5.2e-06	0.000104	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—ERBB2—uterine cancer	5.2e-06	0.000104	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—CTNNB1—uterine cancer	5.19e-06	0.000104	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	5.19e-06	0.000104	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—KRAS—uterine cancer	5.19e-06	0.000104	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—EP300—uterine cancer	5.17e-06	0.000103	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—KRAS—uterine cancer	5.12e-06	0.000102	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—CTNNB1—uterine cancer	5.11e-06	0.000102	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—EP300—uterine cancer	5.11e-06	0.000102	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CXCL8—uterine cancer	5.11e-06	0.000102	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling by GPCR—AKT1—uterine cancer	5.1e-06	0.000102	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling by GPCR—AKT1—uterine cancer	5.08e-06	0.000102	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—HRAS—uterine cancer	5.08e-06	0.000101	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PTEN—uterine cancer	5.06e-06	0.000101	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CXCL8—uterine cancer	5.03e-06	0.0001	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CXCL8—uterine cancer	5.02e-06	0.0001	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—STK11—uterine cancer	5.01e-06	0.0001	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—CYP19A1—uterine cancer	5.01e-06	0.0001	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CXCL8—uterine cancer	5e-06	9.99e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—HRAS—uterine cancer	4.99e-06	9.98e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—EP300—uterine cancer	4.99e-06	9.97e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CDKN1B—uterine cancer	4.99e-06	9.97e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—PIK3CA—uterine cancer	4.99e-06	9.97e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CXCL8—uterine cancer	4.98e-06	9.96e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—HRAS—uterine cancer	4.98e-06	9.96e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PTEN—uterine cancer	4.98e-06	9.96e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—PIK3CA—uterine cancer	4.98e-06	9.96e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—HRAS—uterine cancer	4.97e-06	9.93e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—EP300—uterine cancer	4.96e-06	9.92e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—HRAS—uterine cancer	4.95e-06	9.9e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—PIK3CA—uterine cancer	4.95e-06	9.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling by GPCR—AKT1—uterine cancer	4.94e-06	9.87e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CXCL8—uterine cancer	4.94e-06	9.87e-05	CbGpPWpGaD
Ziprasidone—DRD2—GPCR downstream signaling—AKT1—uterine cancer	4.93e-06	9.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	4.92e-06	9.84e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PTEN—uterine cancer	4.92e-06	9.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	4.91e-06	9.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CDKN1B—uterine cancer	4.91e-06	9.81e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—HRAS—uterine cancer	4.9e-06	9.8e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—KRAS—uterine cancer	4.9e-06	9.8e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CDKN1B—uterine cancer	4.9e-06	9.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—VEGFA—uterine cancer	4.9e-06	9.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	4.89e-06	9.78e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CDKN1B—uterine cancer	4.88e-06	9.76e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—MTHFR—uterine cancer	4.88e-06	9.76e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CDKN1B—uterine cancer	4.87e-06	9.73e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling by GPCR—AKT1—uterine cancer	4.86e-06	9.72e-05	CbGpPWpGaD
Ziprasidone—HTR2A—GPCR downstream signaling—AKT1—uterine cancer	4.86e-06	9.71e-05	CbGpPWpGaD
Ziprasidone—HRH1—GPCR downstream signaling—AKT1—uterine cancer	4.85e-06	9.69e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—PIK3CA—uterine cancer	4.85e-06	9.69e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—NRAS—uterine cancer	4.84e-06	9.67e-05	CbGpPWpGaD
Ziprasidone—CHRM1—GPCR downstream signaling—AKT1—uterine cancer	4.83e-06	9.66e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—EP300—uterine cancer	4.83e-06	9.65e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—TP53—uterine cancer	4.82e-06	9.64e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	4.82e-06	9.64e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CDKN1B—uterine cancer	4.82e-06	9.63e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—TP53—uterine cancer	4.82e-06	9.63e-05	CbGpPWpGaD
Ziprasidone—CHRM3—GPCR downstream signaling—AKT1—uterine cancer	4.81e-06	9.62e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	4.81e-06	9.61e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—TP53—uterine cancer	4.79e-06	9.57e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—PIK3CA—uterine cancer	4.77e-06	9.53e-05	CbGpPWpGaD
Ziprasidone—CHRM2—GPCR downstream signaling—AKT1—uterine cancer	4.77e-06	9.53e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	4.75e-06	9.5e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—EP300—uterine cancer	4.75e-06	9.5e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—VEGFA—uterine cancer	4.73e-06	9.45e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—CTNNB1—uterine cancer	4.71e-06	9.42e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—PIK3CA—uterine cancer	4.7e-06	9.4e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—VEGFA—uterine cancer	4.7e-06	9.4e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—EP300—uterine cancer	4.69e-06	9.38e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—TP53—uterine cancer	4.69e-06	9.37e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—KRAS—uterine cancer	4.67e-06	9.34e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—NRAS—uterine cancer	4.67e-06	9.33e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—NRAS—uterine cancer	4.64e-06	9.28e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—CTNNB1—uterine cancer	4.64e-06	9.27e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—CTNNB1—uterine cancer	4.63e-06	9.25e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—HRAS—uterine cancer	4.61e-06	9.22e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—CTNNB1—uterine cancer	4.61e-06	9.22e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—TP53—uterine cancer	4.61e-06	9.22e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—KRAS—uterine cancer	4.61e-06	9.22e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—HRAS—uterine cancer	4.61e-06	9.21e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—CTNNB1—uterine cancer	4.6e-06	9.19e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PTEN—uterine cancer	4.59e-06	9.18e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—HRAS—uterine cancer	4.58e-06	9.15e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	4.57e-06	9.14e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—VEGFA—uterine cancer	4.57e-06	9.14e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—CTNNB1—uterine cancer	4.55e-06	9.1e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—TP53—uterine cancer	4.55e-06	9.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	4.54e-06	9.08e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	4.54e-06	9.08e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PTEN—uterine cancer	4.52e-06	9.04e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—NRAS—uterine cancer	4.52e-06	9.03e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PTEN—uterine cancer	4.51e-06	9.02e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PTEN—uterine cancer	4.51e-06	9.01e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—PIK3CA—uterine cancer	4.5e-06	9e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—VEGFA—uterine cancer	4.5e-06	9e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PTEN—uterine cancer	4.5e-06	8.99e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—HRAS—uterine cancer	4.48e-06	8.96e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling by GPCR—AKT1—uterine cancer	4.48e-06	8.96e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PTEN—uterine cancer	4.48e-06	8.96e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	4.47e-06	8.93e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—NRAS—uterine cancer	4.45e-06	8.89e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PTEN—uterine cancer	4.44e-06	8.87e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PTEN—uterine cancer	4.43e-06	8.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	4.42e-06	8.83e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—HRAS—uterine cancer	4.41e-06	8.82e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling by GPCR—AKT1—uterine cancer	4.41e-06	8.81e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling by GPCR—AKT1—uterine cancer	4.4e-06	8.8e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—PIK3CA—uterine cancer	4.4e-06	8.79e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling by GPCR—AKT1—uterine cancer	4.39e-06	8.77e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—EP300—uterine cancer	4.38e-06	8.76e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling by GPCR—AKT1—uterine cancer	4.37e-06	8.74e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—TP53—uterine cancer	4.36e-06	8.71e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—HRAS—uterine cancer	4.35e-06	8.7e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling by GPCR—AKT1—uterine cancer	4.33e-06	8.65e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	4.32e-06	8.63e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—EP300—uterine cancer	4.31e-06	8.62e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—EP300—uterine cancer	4.3e-06	8.6e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.3e-06	8.6e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—EP300—uterine cancer	4.3e-06	8.59e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—PIK3CA—uterine cancer	4.29e-06	8.58e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—EP300—uterine cancer	4.29e-06	8.57e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—EP300—uterine cancer	4.27e-06	8.54e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—PIK3CA—uterine cancer	4.27e-06	8.54e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—PIK3CA—uterine cancer	4.23e-06	8.47e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—EP300—uterine cancer	4.23e-06	8.46e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—EP300—uterine cancer	4.22e-06	8.44e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	4.22e-06	8.43e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—HRAS—uterine cancer	4.17e-06	8.33e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—KRAS—uterine cancer	4.16e-06	8.32e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—TP53—uterine cancer	4.15e-06	8.3e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—VEGFA—uterine cancer	4.15e-06	8.29e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PTEN—uterine cancer	4.11e-06	8.22e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—NRAS—uterine cancer	4.1e-06	8.19e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—TP53—uterine cancer	4.1e-06	8.19e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—VEGFA—uterine cancer	4.08e-06	8.16e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—VEGFA—uterine cancer	4.07e-06	8.14e-05	CbGpPWpGaD
Ziprasidone—HTR6—Signaling Pathways—AKT1—uterine cancer	4.07e-06	8.14e-05	CbGpPWpGaD
Ziprasidone—HTR7—Signaling Pathways—AKT1—uterine cancer	4.07e-06	8.13e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—VEGFA—uterine cancer	4.06e-06	8.12e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—VEGFA—uterine cancer	4.05e-06	8.09e-05	CbGpPWpGaD
Ziprasidone—HTR1D—Signaling Pathways—AKT1—uterine cancer	4.04e-06	8.08e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—NRAS—uterine cancer	4.03e-06	8.06e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—NRAS—uterine cancer	4.02e-06	8.04e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—KRAS—uterine cancer	4.02e-06	8.03e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	4.01e-06	8.02e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—NRAS—uterine cancer	4.01e-06	8.02e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—VEGFA—uterine cancer	4.01e-06	8.01e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—NRAS—uterine cancer	4e-06	7.99e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	4e-06	7.99e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—KRAS—uterine cancer	4e-06	7.99e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—HRAS—uterine cancer	3.97e-06	7.94e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—NRAS—uterine cancer	3.96e-06	7.91e-05	CbGpPWpGaD
Ziprasidone—HTR1B—Signaling Pathways—AKT1—uterine cancer	3.96e-06	7.91e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—NRAS—uterine cancer	3.95e-06	7.89e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—EP300—uterine cancer	3.92e-06	7.84e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—HRAS—uterine cancer	3.92e-06	7.83e-05	CbGpPWpGaD
Ziprasidone—DRD4—Signaling Pathways—AKT1—uterine cancer	3.89e-06	7.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—KRAS—uterine cancer	3.89e-06	7.77e-05	CbGpPWpGaD
Ziprasidone—CHRM4—Signaling Pathways—AKT1—uterine cancer	3.84e-06	7.68e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—KRAS—uterine cancer	3.83e-06	7.65e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—PIK3CA—uterine cancer	3.82e-06	7.64e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—PIK3CA—uterine cancer	3.78e-06	7.56e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—MTHFR—uterine cancer	3.77e-06	7.53e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	3.71e-06	7.42e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—TP53—uterine cancer	3.7e-06	7.39e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—PIK3CA—uterine cancer	3.69e-06	7.38e-05	CbGpPWpGaD
Ziprasidone—CHRM5—Signaling Pathways—AKT1—uterine cancer	3.68e-06	7.36e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—PIK3CA—uterine cancer	3.67e-06	7.34e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—NRAS—uterine cancer	3.67e-06	7.33e-05	CbGpPWpGaD
Ziprasidone—CYP3A7—Metabolism—AKT1—uterine cancer	3.59e-06	7.18e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—PIK3CA—uterine cancer	3.57e-06	7.14e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—TP53—uterine cancer	3.57e-06	7.14e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—TP53—uterine cancer	3.55e-06	7.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—HRAS—uterine cancer	3.54e-06	7.07e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—KRAS—uterine cancer	3.53e-06	7.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—PIK3CA—uterine cancer	3.51e-06	7.03e-05	CbGpPWpGaD
Ziprasidone—DRD1—Signaling Pathways—AKT1—uterine cancer	3.51e-06	7.01e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Metabolism—AKT1—uterine cancer	3.49e-06	6.98e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—KRAS—uterine cancer	3.47e-06	6.94e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—PIK3CA—uterine cancer	3.47e-06	6.94e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—KRAS—uterine cancer	3.46e-06	6.92e-05	CbGpPWpGaD
Ziprasidone—DRD3—Signaling Pathways—AKT1—uterine cancer	3.46e-06	6.92e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—TP53—uterine cancer	3.46e-06	6.91e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—KRAS—uterine cancer	3.45e-06	6.9e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—KRAS—uterine cancer	3.44e-06	6.88e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—HRAS—uterine cancer	3.41e-06	6.83e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—KRAS—uterine cancer	3.41e-06	6.81e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—TP53—uterine cancer	3.4e-06	6.8e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—KRAS—uterine cancer	3.4e-06	6.79e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—HRAS—uterine cancer	3.4e-06	6.79e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—HRAS—uterine cancer	3.3e-06	6.61e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—HRAS—uterine cancer	3.25e-06	6.5e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—PIK3CA—uterine cancer	3.24e-06	6.48e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PTEN—uterine cancer	3.2e-06	6.41e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—PIK3CA—uterine cancer	3.19e-06	6.37e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—PIK3CA—uterine cancer	3.18e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—PIK3CA—uterine cancer	3.18e-06	6.36e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—PIK3CA—uterine cancer	3.17e-06	6.34e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—PIK3CA—uterine cancer	3.16e-06	6.32e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—KRAS—uterine cancer	3.16e-06	6.31e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—TP53—uterine cancer	3.13e-06	6.27e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—PIK3CA—uterine cancer	3.13e-06	6.26e-05	CbGpPWpGaD
Ziprasidone—ADRA2B—Signaling Pathways—AKT1—uterine cancer	3.12e-06	6.24e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	3.12e-06	6.24e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Metabolism—AKT1—uterine cancer	3.09e-06	6.17e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—TP53—uterine cancer	3.08e-06	6.17e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—TP53—uterine cancer	3.08e-06	6.15e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—TP53—uterine cancer	3.07e-06	6.13e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—TP53—uterine cancer	3.06e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—EP300—uterine cancer	3.06e-06	6.11e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—TP53—uterine cancer	3.03e-06	6.05e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—TP53—uterine cancer	3.02e-06	6.04e-05	CbGpPWpGaD
Ziprasidone—HTR1A—Signaling Pathways—AKT1—uterine cancer	3.02e-06	6.03e-05	CbGpPWpGaD
Ziprasidone—HTR2C—Signaling Pathways—AKT1—uterine cancer	3e-06	6e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—HRAS—uterine cancer	3e-06	5.99e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—HRAS—uterine cancer	2.95e-06	5.9e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—HRAS—uterine cancer	2.94e-06	5.88e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—HRAS—uterine cancer	2.93e-06	5.87e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—HRAS—uterine cancer	2.92e-06	5.85e-05	CbGpPWpGaD
Ziprasidone—ADRA2C—Signaling Pathways—AKT1—uterine cancer	2.92e-06	5.83e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	2.9e-06	5.8e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—HRAS—uterine cancer	2.9e-06	5.79e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—HRAS—uterine cancer	2.89e-06	5.77e-05	CbGpPWpGaD
Ziprasidone—ADRA1B—Signaling Pathways—AKT1—uterine cancer	2.87e-06	5.74e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Metabolism—AKT1—uterine cancer	2.83e-06	5.67e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—TP53—uterine cancer	2.81e-06	5.61e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PTEN—uterine cancer	2.71e-06	5.43e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—HRAS—uterine cancer	2.68e-06	5.37e-05	CbGpPWpGaD
Ziprasidone—DRD2—Signaling Pathways—AKT1—uterine cancer	2.65e-06	5.29e-05	CbGpPWpGaD
Ziprasidone—HTR2A—Signaling Pathways—AKT1—uterine cancer	2.6e-06	5.21e-05	CbGpPWpGaD
Ziprasidone—HRH1—Signaling Pathways—AKT1—uterine cancer	2.6e-06	5.2e-05	CbGpPWpGaD
Ziprasidone—CYP3A5—Metabolism—AKT1—uterine cancer	2.6e-06	5.19e-05	CbGpPWpGaD
Ziprasidone—CHRM1—Signaling Pathways—AKT1—uterine cancer	2.59e-06	5.18e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—EP300—uterine cancer	2.59e-06	5.18e-05	CbGpPWpGaD
Ziprasidone—CHRM3—Signaling Pathways—AKT1—uterine cancer	2.58e-06	5.16e-05	CbGpPWpGaD
Ziprasidone—CHRM2—Signaling Pathways—AKT1—uterine cancer	2.56e-06	5.11e-05	CbGpPWpGaD
Ziprasidone—ADRA1A—Signaling Pathways—AKT1—uterine cancer	2.55e-06	5.1e-05	CbGpPWpGaD
Ziprasidone—ADRA2A—Signaling Pathways—AKT1—uterine cancer	2.37e-06	4.74e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—PIK3CA—uterine cancer	2.26e-06	4.52e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PTEN—uterine cancer	2.1e-06	4.19e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—EP300—uterine cancer	2e-06	3.99e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.92e-06	3.83e-05	CbGpPWpGaD
Ziprasidone—CYP2D6—Metabolism—AKT1—uterine cancer	1.85e-06	3.69e-05	CbGpPWpGaD
Ziprasidone—CYP1A2—Metabolism—AKT1—uterine cancer	1.56e-06	3.13e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.48e-06	2.95e-05	CbGpPWpGaD
Ziprasidone—CYP3A4—Metabolism—AKT1—uterine cancer	1.21e-06	2.41e-05	CbGpPWpGaD
